{{Drugbox
| IUPAC_name = Methyl (2''S'')-2-{[1-(5-fluoropentyl)-1''H''-indazol-3-yl]formamido}-3-methylbutanoate
| image = 5F-AMB-PINACA.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category =  
| legal_AU = 
| legal_CA = Schedule II
| legal_UK = 
| legal_US = Schedule I
| legal_DE = Anlage II
| legal_status = Illegal in China, Japan, Sweden, Singapore, 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1801552-03-3
| CAS_supplemental  = (''S''-isomer) <BR>1715016-74-2 ([[racemic mixture|racemate]])
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 119025812
| ChemSpiderID      = 30646783
| UNII = DK24ID0BCL

<!--Chemical data-->
| C=19 | H=26 | F=1 | N=3 | O=3
| molecular_weight =
| smiles            = O=C(N[C@H](C(OC)=O)C(C)C)C1=NN(CCCCCF)C2=C1C=CC=C2
| StdInChI = 1S/C19H26FN3O3/c1-13(2)16(19(25)26-3)21-18(24)17-14-9-5-6-10-15(14)23(22-17)12-8-4-7-11-20/h5-6,9-10,13,16H,4,7-8,11-12H2,1-3H3,(H,21,24)/t16-/m0/s1
| StdInChIKey = SAFXSUZMRLTBMM-INIZCTEOSA-N
}}

'''5F-AMB''' (also known as '''5F-MMB-PINACA''' and '''5F-AMB-PINACA''') is an [[indazole]]-based synthetic [[cannabinoid]] from the indazole-3-carboxamide family,<ref>{{cite web | url=https://www.caymanchem.com/Product.vm/catalog/15489 | title=5-Fluoro-AMB | publisher=Cayman Chemical | accessdate=22 June 2015}}</ref> which has been used as an active ingredient in [[synthetic cannabis]] products. It was first identified in Japan in early 2014.<ref>{{cite journal | url=https://link.springer.com/article/10.1007%2Fs11419-014-0238-5 | title=Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products | author=Nahoko Uchiyama | author2=Yoshihiko Shimokawa | author3=Maiko Kawamura| author4=Ruri Kikura-Hanajiri | author5=Takashi Hakamatsuka | journal=Forensic Toxicology |date=August 2014  | volume=32 | issue=2 | pages=266–281 | doi=10.1007/s11419-014-0238-5}}</ref><ref name="Shevyrin_2015">{{cite journal | vauthors = Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT | title = Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group | journal = Analytical and Bioanalytical Chemistry | date = Apr 2015 | pmid = 25893797 | doi = 10.1007/s00216-015-8612-7 | url = https://link.springer.com/article/10.1007%2Fs00216-015-8612-7 | volume=407 | pages=6301–15}}</ref>
Although only very little pharmacological information about 5F-AMB itself exists,<ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/rcm.7538/abstract | title=Metabolic profiling of new synthetic cannabinoids AMB and 5F-AMB by human hepatocyte and liver microsome incubations and high-resolution mass spectrometry | author=Maria Andersson | author2=Xingxing Diao | author3=Ariane Wohlfarth| author4=Karl B. Scheidweiler | author5=Marilyn A. Huestis | journal=Rapid Communications in Mass Spectrometry | date=30 April 2016 | volume=30 | issue=8 | pages=1067–107 | doi=10.1002/rcm.7538 | pmid=27003044}}</ref> its 4-cyanobutyl analogue (instead of 5-fluoropentyl) has been reported to be a potent [[agonist]] for the [[CB1 receptor|CB<sub>1</sub> receptor]] (''K''<sub>I</sub>&nbsp;=&nbsp;0.7&nbsp;nM).<ref>[http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009106980 Buchler IP et al., INDAZOLE DERIVATIVES. WO 2009/106980]</ref><ref>{{cite journal|first1=Samuel D.|last1=Banister|first2=Mitchell|last2=Longworth|first3=Richard|last3=Kevin|first4=Shivani|last4=Sachdev|title=Pharmacology of Valinate and ''tert''-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues|url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00137|journal=ACS Chemical Neuroscience|date=27 July 2016|doi=10.1021/acschemneuro.6b00137|pmid=27421060|first5=Marina|last5=Santiago|first6=Jordyn|last6=Stuart|first7=James B. C.|last7=Mack|first8=Michelle|last8=Glass|first9=Iain S.|last9=McGregor|first10=Mark|last10=Connor|first11=Michael|last11=Kassiou|volume=7|pages=1241–54}}</ref>

==Side effects==

5F-AMB intoxication caused one fatality on its own<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0379073816300901 | title=Death after Use of the Synthetic Cannabinoid 5F-AMB | author=Kevin G. Shanks | author2=George S. Behonick | journal=Forensic Science International | date=May 2016 | volume=262 | pages=e21–e24 | doi=10.1016/j.forsciint.2016.03.004 | pmid=27017174}}</ref> and another one through [[ketoacidosis]] in combination with [[AB-CHMINACA]], [[AB-FUBINACA]], [[AM-2201]], [[5F-APINACA]], [[EAM-2201]], [[JWH-018]], [[JWH-122]], [[MAM-2201]], [[STS-135 (drug)|STS-135]] and [[THJ-2201]] and another fatality in combination with [[AB-CHMINACA]] and [[Diphenidine]].<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0379073815003564 | title=Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? | author=C. Hess | author2=S. Stockhausen | author3=G. Kernbach-Wighton| author4=B. Madea | journal=Forensic Science International |date=August 2015  | doi=10.1016/j.forsciint.2015.08.012 | pmid=26363623 | volume=257 | pages=e6–e11}}</ref><ref>{{cite journal | url=https://link.springer.com/article/10.1007%2Fs11419-014-0245-6 | title=Postmortem distribution of AB-CHMINACA, 5-fluoro-AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning case: usefulness of adipose tissue for detection of the drugs in unchanged forms | author=Koutaro Hasegawa | author2=Amin Wurita | author3=Kayoko Minakata| author4=Kunio Gonmori | author5=Hideki Nozawa| author6=Itaru Yamagishi | author7=Kanako Watanabe| author8=Osamu Suzuki | journal=Forensic Toxicology |date=January 2015  | volume=33 | issue=1 | pages=45–53 | doi=10.1007/s11419-014-0245-6}}</ref>

==Legality==

In the United States, 5F-AMB is a [[Controlled_Substances_Act#Schedule_I_controlled_substances|Schedule I controlled substance]].<ref>{{cite web | url = https://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr1221.htm | title = Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I | publisher = [[Drug Enforcement Administration]]}}</ref>

5F-AMB is an [[Drugs controlled by the German Betäubungsmittelgesetz|Anlage II]] controlled substance in Germany as of May 2015.<ref>{{cite web | url=http://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html | title=Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel) | language=German | accessdate=22 June 2015}}</ref>

Sweden's public health agency suggested classifying 5F-AMB as hazardous substance on November 10, 2014.<ref>{{cite web | url=https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/ | title=Cannabinoider föreslås bli klassade som hälsofarlig vara | publisher=Folkhälsomyndigheten | language=Swedish | accessdate=29 June 2015}}</ref>

The state of Louisiana banned 5F-AMB through an emergency rule after it was detected in a [[synthetic cannabinoids]] product called "Kali Berry 2" on 3 June 2014.<ref>{{cite web | url=http://dhh.louisiana.gov/index.cfm/newsroom/detail/3059 | title=DHH Adds Two New Synthetic Marijuana Compounds to Banned List | publisher=Louisiana Department of Health and Hospitals | date=3 June 2014 | accessdate=22 July 2015}}</ref>

5F-AMB is controlled by the Fifth Schedule of the Misuse of Drugs Act (MDA) in Singapore as of May 2015.<ref>{{cite web | url=http://www.cnb.gov.sg/Libraries/CNB_Newsroom_Files/CNB_NR_-_30_Apr_2015.sflb.ashx | title=CNB NEWS RELEASE | publisher=Central Narcotics Bureau (CNB) | date=30 April 2015 | accessdate=24 July 2015}}</ref>

5F-AMB was also scheduled in Japan on July 25, 2014.<ref>{{cite web | url=http://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/dl/meisho.pdf | title=指定薬物一覧 | publisher=Ministry of Health, Labour and Welfare | language=Japanese}}</ref>

As of October 2015 5F-AMB is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-AB-PINACA]]
* [[5F-ADB]]
* [[5F-APINACA]]
* [[AB-CHMINACA]]
* [[AB-FUBINACA]]
* [[AB-CHFUPYCA]]
* [[AB-PINACA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[ADB-PINACA]]
* [[ADBICA]]
* [[AMB-FUBINACA]]
* [[APICA]]
* [[APINACA]]
* [[MDMB-CHMICA]]
* [[MDMB-FUBINACA]]
* [[MMB-2201]]
* [[PX-3]]
{{Div col end}}

==References==
{{Reflist}}

{{Cannabinoids}}

[[Category:Indazoles]]
[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Fluoroalkanes]]
[[Category:Indazolecarboxamides]]